Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 to 45 years on the Day of screening;~* Has a BMI of ≥ 18.5 and \< 30 kg/m2 on the Day of screening;~* Understanding of the study and its procedures, agrees to its provisions, and gives written informed consent prior to any study-related procedures;~* Generally healthy as determined by the Investigator's clinical judgement based on medical history, physical examination and screening laboratory tests;~* If female, subject is of non-childbearing potential. The definition of non-childbearing potential includes the following:~  1. Surgically sterile (e.g., hysterectomy with or without oophorectomy; fallopian tube ligation; endometrial ablation), at least 30 days prior to signature of the Informed Consent form;~ 2. At least 5 years post-menopause (i.e., 6 years post last menstrual period), or menopause confirmed by follicle-stimulating hormone (FSH) testing.~Exclusion Criteria:~* History of known CHIKV infection;~* Plans to travel to areas with active CHIKV transmission during the course of the study or history of travel to an endemic CHIKV area within 4 weeks prior to study enrollment;~* Participation in a clinical study involving an investigational CHIKV vaccine;~* Receipt of an inactivated vaccine within 4 weeks or live vaccine within 8 weeks prior to vaccination in this study;~* Positive test results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV);~* (1) Abnormal laboratory liver function values (≥ grade 1), (2) any grade 1 abnormal lab values deemed clinically relevant by the Investigator, and (3) any ≥ grade 2 abnormal lab values irrespective of clinical significance at screening;~* Clinically significant abnormal ECG at screening;~* History of significant cardiovascular, respiratory (including asthma), metabolic, neurological, hepatic, rheumatic, autoimmune, hematological, gastrointestinal or renal disorder;~* History of immune-mediated or clinically significant arthritis/arthralgia;~* History of malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved a cure;~* Disease or recent or current treatment that can be expected to influence immune response as specified in the protocol;~* History of severe hypersensitivity reactions or anaphylaxis;~* History of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of the candidate vaccine, other known contraindications);~* Acute febrile infections within two weeks prior to vaccination;~* Subject is of childbearing potential or lactating at the time of enrollment;~* Blood donation within 30 days or receipt of blood-derived products (e.g. plasma) within 90 days prior to vaccination in this study or during the course of the study;~* A rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating;~* Known or suspected problem with alcohol or drug abuse as determined by the Investigator;~* Any condition that, in the opinion of the Investigator, may compromise the subjects well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study;~* Participation in another clinical study involving an investigational medicinal product within 30 days prior to study enrollment or during the course of this study;~* Member of the team conducting the study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- VLA1553 low dose (Type: ACTIVE_COMPARATOR): VLA1553 with 3.2x10\^3 TCID50/ 100 µL (microliter). Re-vaccination at Month 12 with VLA1553 with 3.2x10\^5 TCID50/ 1 mL (milliliter)
- VLA1553 medium dose (Type: ACTIVE_COMPARATOR): VLA1553 with 3.2x10\^4 TCID50/ 1 mL Re-vaccination at Month 12 with VLA1553 with 3.2x10\^5 TCID50/ 1 mL
- VLA1553 high dose (Type: ACTIVE_COMPARATOR): VLA1553 with 3.2x10\^5 TCID50/ 1 mL Re-vaccination at Month 6 or Month 12 with VLA1553 with 3.2x10\^5 TCID50/ 1 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete